<DOC>
	<DOCNO>NCT02824055</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , three period crossover study evaluate effect RO5545965 function key brain circuitry involve negative symptom use functional magnetic resonance imaging ( fMRI ) reward-based learn stable participant mild moderate negative symptom schizophrenia treat antipsychotic . Participants randomize one six different sequence participant receive three 3-week treatment course RO5545965 5 milligram ( mg ) , RO5545965 15 mg placebo . Each treatment period separate washout period 14 day . Total duration study approximately 17 week .</brief_summary>
	<brief_title>A Study Evaluate The Effects RO5545965 Participants With Negative Symptoms Schizophrenia Treated With Antipsychotics</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>A diagnostic statistical manual mental disorders5 ( DSM5 ) diagnosis schizophrenia establish structured clinical interview DSM5clinical trial ( SCID5CT ) screen Participants hospitalization worsen schizophrenia within 3 month prior screen Male female participant childbearing capacity ; female must either surgically sterile postmenopausal least 1 year Body mass index ( BMI ) great ( &gt; ) 18.5 kilogram per square meter ( kg/m^2 ) less ( &lt; ) 35 kg/m^2 Fluent English , even English primary language Participants clinical global impressionseverity ( CGIS ) score great equal ( &gt; /= ) 3 ( mildly ill ) Participants score less equal ( &lt; /= ) 4 ( moderate ) positive negative syndrome scale ( PANSS ) item P7 ( hostility ) , G8 ( uncooperativeness ) G6 ( depression ) Participants PANSS negative symptom factor score &gt; /=18 Participants calgary depression rating scale schizophrenia ( CDSS ) score &lt; /=8 Participants stable treatment , 6 week without change , two antipsychotic prior screen Moderate severe substance use disorder within 6 month define DSM5 Positive urine drug screen amphetamine , methamphetamine , opiate , buprenorphine , methadone , cannabinoids , cocaine barbiturate Participants significant risk suicide harm others accord Investigator 's judgment History neuroleptic malignant syndrome A prior current general medical condition might impair cognition psychiatric function A movement disorder due antipsychotic treatment currently control antiextrapyramidal symptom ( antiEPS ) treatment another movement disorder might affect rating EPS scale Participants score &gt; 2 ( mild ) four CGIS item extrapyramidal symptom rating scale ( ESRSA ) History human immunodeficiency virus ( HIV ) infection , Hepatitis B , Hepatitis C infection QTcF interval &gt; 450 millisecond ( msec ) ( 470 msec female ) significant abnormality screen electrocardiogram ( ECG ) base centralized reading Clinically significant abnormality laboratory safety test result Significant unstable physical condition Receipt investigational drug within 90 day 5 time halflife investigational drug , whatever longer , prior screen Previously receive RO5545965 Electroconvulsive treatment ( ECT ) within 6 month prior screen Current 6 month prior screen treatment olanzapine clozapine Change benzodiazepine sleep medication regimen within 2 week prior screen Change antiEPS medication within two week prior screen Use prohibit medication take within 14 day within 5 time elimination halflife medication first study drug administration Use strong moderate inhibitor cytochrome P 450 3A ( CYP3A ) CYP2C8 inducer CYP3A within 14 day within 5 time elimination halflife medication ( whichever longer ) first study drug administration Use nutrient know modulate CYP3A activity within 1 week first study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>